Monthly
Flexibility with month-to-month billing.
- Compounded TB-500 therapy
- Licensed clinician oversight
- Care-team messaging
- Free discreet shipping
TB-500, a synthetic fragment of Thymosin Beta-4, is utilized in advanced wellness protocols to support cellular migration and tissue repair. Truvera’s TB-500 Regenerative Therapy is tailored for individuals seeking enhanced recovery and improved physical performance under medical supervision.
Potential Benefits
Short Version
Advanced regenerative peptide therapy supporting recovery and physical performance.
Peptide · Regenerative Therapy
TB-500 is a synthetic fragment of Thymosin Beta-4, studied for its ability to promote cell migration, angiogenesis, and anti-inflammatory signaling in damaged tissue. Prescribed by a licensed clinician, compounded to order, and shipped to your door.
How it works
From online intake to medication delivered — in as little as 3 days.
A 5-minute medical intake covers your health history, injury background, current medications, and recovery goals. No appointment needed.
A licensed US clinician reviews your intake and, if clinically appropriate, issues your TB-500 prescription and compounding order.
Your TB-500 is compounded at a licensed US pharmacy and shipped in discreet, temperature-controlled packaging.
Message your care team anytime. We monitor your healing progress and adjust your protocol at every check-in.
Pricing
One monthly price covers your clinician visits, compounded medication, shipping, and care team access.
Flexibility with month-to-month billing.
Save 17% vs monthly
Best balance of savings and commitment.
Save 28% vs monthly
Our best price for long-term regenerative support.
TB-500 is a compounded peptide, not an FDA-approved drug. Prescriptions are issued only at the discretion of licensed clinicians and only when medically appropriate.
Eligibility
What is TB-500?
Thymosin Beta-4 (TB4) is a 43-amino-acid peptide found in virtually every cell in the human body. First characterized in thymic tissue, it plays a central role in embryonic development — particularly in cardiac and vascular formation — and continues to support tissue homeostasis throughout adult life. TB4 is one of the most abundant intracellular peptides known, accumulating at sites of injury where it coordinates the early stages of cellular repair. TB-500 is a synthetic fragment comprising amino acids 17–23 of the full TB4 sequence, identified as the domain responsible for the peptide's bioactive effects on actin dynamics.
The core mechanism of TB-500 is G-actin sequestration: it binds free actin monomers, preventing premature polymerization and enabling rapid cytoskeletal reorganization that drives cell migration. This is not merely structural — by facilitating migration of keratinocytes, endothelial cells, and myoblasts into injured tissue, TB-500 directly initiates the cellular cascades required for wound closure, angiogenesis, and myofiber repair. Research has examined TB-500 in models of cardiac tissue repair following ischemic injury, tendon and ligament healing, and dermal wound closure. Studies have also reported modulation of anti-inflammatory cytokines including reduced TNF-a and IL-6 expression at injury sites, complementing the mechanical repair process with an immunomodulatory effect.
TB-500 is frequently compared with BPC-157, another compounded regenerative peptide. The two operate through distinct mechanisms — BPC-157 primarily acts on nitric oxide signaling and growth factor upregulation, while TB-500 works through actin-binding and direct promotion of cell migration and angiogenesis. Clinically, they are considered complementary rather than interchangeable. TB-500 has not been approved by the FDA as a standalone drug and is available in the US exclusively through licensed clinicians via Section 503A compounding pharmacies.
Patient experience
"I tore a ligament in my ankle last year and it just wasn't healing the way my PT expected. After six weeks on TB-500 I was back to full training — my follow-up imaging showed tissue remodeling my surgeon described as ahead of schedule."
"Chronic Achilles tendinopathy kept sidelining me for years. Two months into the protocol the pain on loading is dramatically reduced. The TruVera intake was thorough and my clinician walked me through exactly why this approach made sense for my case."
"I was skeptical — I've tried a lot of recovery modalities. TB-500 is the first thing that actually felt like it was accelerating tissue repair rather than just managing symptoms. Eight weeks in and I'm back to full-intensity workouts."
FAQ
TB-500 is a synthetic peptide fragment (amino acids 17–23) of Thymosin Beta-4, a naturally occurring protein involved in tissue repair and cellular regeneration. It is not FDA-approved as a standalone drug. TruVera provides TB-500 through licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act — available only with a valid prescription from a licensed clinician who determines it is medically appropriate for your situation.
TB-500 and BPC-157 are both compounded regenerative peptides, but they work through distinct mechanisms. TB-500 functions primarily through G-actin sequestration — binding free actin monomers to enable cell migration and angiogenesis. BPC-157 primarily acts on nitric oxide signaling pathways and upregulation of growth factors including VEGF and EGF receptors. Because their mechanisms are complementary rather than redundant, some clinicians prescribe both depending on the injury profile. Your TruVera clinician will evaluate which approach, or combination, is appropriate for your case.
TB-500 is administered via subcutaneous injection, typically using a small-gauge insulin syringe. Protocols generally consist of a loading phase — higher-frequency dosing over the first 4–6 weeks — followed by a maintenance phase at reduced frequency. Your clinician will specify your exact dose and injection schedule during your consultation and provide detailed instructions for self-administration.
Most patients begin to notice early signs of improved tissue function — reduced pain on loading, improved range of motion, faster workout recovery — within 4–8 weeks of consistent use during the loading phase. The timeline varies based on injury severity, tissue type, and individual healing capacity. Your clinician will evaluate your progress at regular check-ins and adjust the protocol as needed.
TB-500 is generally well tolerated. The most commonly reported effects are mild injection-site reactions (redness, transient soreness) and occasional fatigue during the loading phase as the body responds to more frequent dosing. Because Thymosin Beta-4 promotes angiogenesis, TB-500 is contraindicated in patients with active cancer — the same mechanism that supports tissue repair could theoretically support tumor vascularization. Long-term human safety data is limited given the absence of completed clinical trials. Your clinician will review your full health history before prescribing.
Yes. You can pause or cancel at any time through your TruVera patient portal — no phone calls, no cancellation fees. If you have questions about your protocol before canceling, your care team is always available to discuss adjustments or alternative approaches.